Clinical trials: in Indonesia
Mucopolysaccharidosis I (MPS I)
Mucopolysaccharidosis I (MPS I) Registry
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I.
- Trial name
- NCT00144794
- Where
- 141 sites in United States, Argentina and 35 more
- Volunteers
- 1,406 people
- Sponsor
- Genzyme, a Sanofi Company
Retinitis Pigmentosa
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells.
- Trial name
- NCT05909488
- Testing
- 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CM
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Polycystic Ovary Syndrome
Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.
The purpose of this study is to investigating the effect of Umbilical Cord Mesenchymal Stem Cell (UC-MSCs) and secretomes to insulin resistance in Polycystic Ovary Syndrome (PCOS) patients.
- Trial name
- NCT05279768
- Testing
- UC-MSCs, Secretomes, UC-MSCs and Secretomes
- Where
- Indonesia
- Volunteers
- 44 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Nasopharyngeal Cancer
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.
- Trial name
- NCT05261750
- Testing
- Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy), Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy)
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Retinitis Pigmentosa
Long-term Safety of UC-MSC Transplantation in Patients With Retinitis Pigmentosa
The study will perform to follow-up UC-MSCs and CM transplantation. 18 patients will be called back to be examined after 5 years of UC-MSC and/or CM transplantation.
- Trial name
- NCT05786287
- Testing
- Conditioned Medium (CM), Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
- Where
- 2 sites in Indonesia
- Volunteers
- 18 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Ischemic Stroke
Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct
The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to…
- Trial name
- NCT05008588
- Testing
- Conditioned Medium, Umbilical Cord Mesenchymal Stem Cells, Neurologic and Neutrophic Drugs
- Where
- 2 sites in Indonesia
- Volunteers
- 15 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Cerebral Palsy
Stem Cell and Conditioned Medium for Cerebral Palsy
The aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (UCMSCs) and conditioned medium (CM) administration, UCMSCs only and control with standard therapy.
- Trial name
- NCT04314687
- Testing
- Umbilical Cord Mesenchymal Stem Cells, Conditioned Medium, Standard Therapy
- Where
- Indonesia
- Volunteers
- 78 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Osteoarthritis, Knee
Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis
This study aims to compare the efficacy of Umbilical Cord Mesenchymal Stem Cell and secretome between arthroscopy and without arthroscopy intervention in OA patients.
- Trial name
- OA (NCT04314661)
- Testing
- Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome, Arthroscopy with Secretome + Mesenchymal Stem Cells + Secretome, Non Arthroscopy with Mesenchymal Stem Cells + Secretome + Secretome
- Where
- Indonesia
- Volunteers
- 31 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Liver Cirrhoses
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
The study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by Hepatitis B.
- Trial name
- NCT04357600
- Testing
- Allogeneic Umbilical Cord Mesenchymal Stem Cell
- Where
- Indonesia
- Volunteers
- 12 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Androgenetic Alopecia
Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients
This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr.
- Trial name
- NCT07429253
- Testing
- Secretome, Platelet-Rich Plasma (PRP) Injections
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Cough
The Efficacy and Safety of Reconyl in Acute Cough Treatment
This is a 2-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing Reconyl at a dose of 225 mg three times daily and Reconyl Placebo three times daily for a 7-day course of therapy.
- Trial name
- NCT07420491
- Testing
- Reconyl
- Where
- Indonesia
- Volunteers
- 144 people
- Sponsor
- Dexa Medica Group
Lactation Induced
Supplementation of Galatonol 300 mg / Striatin 30 mg in Postpartum Lactating Mothers
This is a randomized, double-blind, and placebo-controlled study involving mothers as the participant and participant's babies evaluating the effect of a 15-day-supplementation with a product containing extracts derived from a…
- Trial name
- NCT06558071
- Testing
- Galatonol 300 mg/Striatin 30 mg
- Where
- 10 sites in Indonesia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Functional Dyspepsia
DLBS2411 Treatment For Functional Dyspepsia
This is a 2-arm, prospective, double-blind, randomized and placebo-controlled study using DLBS2411 at a dose of 250 mg twice daily (before morning and evening meals), for a 4-week course of therapy, for the treatment of patients…
- Trial name
- NCT05248802
- Testing
- DLBS2411
- Where
- 8 sites in Indonesia
- Volunteers
- 106 people
- Sponsor
- Dexa Medica Group
Diabetic Nephropathy Type 2
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial
The goal of this clinical trial is to evaluate the safety and efficacy of a single intra-renal injection of allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) in adults with diabetic nephropathy aged 40 to 65…
- Trial name
- NCT07396155
- Testing
- Umbilical Cord Mesenchymal Stem Cells
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Chronic Kidney Disease
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney…
- Trial name
- NCT00858637
- Testing
- MCI-196, Simvastatin
- Where
- 39 sites in Belarus, Bulgaria and 11 more
- Volunteers
- 260 people
- Sponsor
- Tanabe Pharma Corporation
Diabetic Kidney Disease (DKD)
Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease
The goal of this single-arm, open-label clinical trial is to evaluate the effects of subcutaneous autologous dendritic cell (DC) and lymphocyte administration on albuminuria and endothelial dysfunction in Type 2 Diabetes Mellitus…
- Trial name
- NCT06866158
- Testing
- Dendritic cell immunotherapy
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- PT. JES Kasih Nusantara Sejahterah
Breast Cancer Female, Stage II Breast Cancer
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
- Conditions
- Breast Cancer Female, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
- Trial name
- BRAVA (NCT06087120)
- Where
- 3 sites in Indonesia, Vietnam
- Volunteers
- 125 people
- Sponsor
- Gene Solutions
HER2-negative
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
This noninterventional, multicenter,retrospective study has been proposed to estimate the prevalence, clinicopathological characteristics,treatment patterns and clinical outcomes of human epidermal growth factor receptor 2…
- Trial name
- iRetroBC (NCT06131424)
- Where
- 31 sites in Argentina, Brazil and 11 more
- Volunteers
- 1,151 people
- Sponsor
- AstraZeneca
COVID-19
Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19
AD17002 enhances nasal mucosal innate immunity and has met safety and efficacy endpoints in studies of nasal adjuvants or intranasal immunomodulators.
- Trial name
- NCT05541510
- Testing
- AD17002 + Formulation buffer
- Where
- 3 sites in Indonesia
- Volunteers
- 180 people
- Sponsor
- Advagene Biopharma Co. Ltd.
Coronary Artery Disease
DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System
The goal of this registry is to confirm the safety, and performance of the DynamX Coronary Bioadaptor System in patients with coronary artery disease.
- Trial name
- Bio-RESTORE (NCT06074549)
- Testing
- DynamX Novolimus-eluting Coronary Bioadaptor System
- Where
- 17 sites in Austria, Curacao and 7 more
- Volunteers
- 5,000 people
- Sponsor
- Elixir Medical Corporation